<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">19011288</PMID><DateCompleted><Year>2009</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0301-3073</ISSN><JournalIssue CitedMedium="Print"><Volume>37</Volume><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Frontiers of hormone research</Title><ISOAbbreviation>Front Horm Res</ISOAbbreviation></Journal><ArticleTitle>The role of the CAG repeat androgen receptor polymorphism in andrology.</ArticleTitle><Pagination><StartPage>52</StartPage><EndPage>61</EndPage><MedlinePgn>52-61</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1159/000175843</ELocationID><Abstract><AbstractText>A dysfunctional androgen receptor is able to cause variable phenotypes of androgen insensitivity or androgenicity in humans. In addition, also a polymorphism, the CAG repeat polymorphism in exon 1 of the androgen receptor gene (CAG)n, modulates androgen effects: androgen-induced target activities are attenuated corresponding to the length of triplet residues. Clinically, the (CAG)n polymorphism causes marked modulations of androgenicity in eugonadal men in various tissues and psychological traits and may cause the clinical picture of hypogonadism in the presence of normal testosterone concentrations. Also pharmacogenetic implications might exist in this regard: there appears to be a significant role of testosterone treatment of hypogonadal men as treatment effects have been demonstrated to be modulated by the number of (CAG)n in retrospective approaches.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zitzmann</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Reproductive Medicine, Universit&#xe4;tsklinikum M&#xfc;nster, M&#xfc;nster, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Horm Res</MedlineTA><NlmUniqueID>0320246</NlmUniqueID><ISSNLinking>0301-3073</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C410798">AR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011944">Receptors, Androgen</NameOfSubstance></Chemical><Chemical><RegistryNumber>3XMK78S47O</RegistryNumber><NameOfSubstance UI="D013739">Testosterone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015519" MajorTopicYN="N">Bone Density</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055534" MajorTopicYN="N">Bulbo-Spinal Atrophy, X-Linked</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007006" MajorTopicYN="N">Hypogonadism</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011471" MajorTopicYN="N">Prostatic Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011944" MajorTopicYN="N">Receptors, Androgen</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013739" MajorTopicYN="N">Testosterone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018911" MajorTopicYN="Y">Trinucleotide Repeats</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>47</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>11</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>2</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>11</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19011288</ArticleId><ArticleId IdType="doi">10.1159/000175843</ArticleId><ArticleId IdType="pii">000175843</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>